Product Dossier
ADAKVEO
Product Dossier for ADAKVEO (crizanlizumab, Novartis Pharmaceuticals). ARTG record, PBS listing, PBAC outcomes, AusPAR — compiled by arcimedes.
- Sponsor: Novartis Pharmaceuticals
- Active ingredient: crizanlizumab
- Therapeutic area: Haematology
- Same area: REVOLADE
- Same area: NOVICRIT
What it is
ADAKVEO is crizanlizumab 10 mg/mL concentrate for solution for infusion.
Approved indications
— Prevention of recurrent vaso-occlusive crises in patients aged 16 years and older with sickle cell disease.
Regulatory history
ADAKVEO received approval on 2021-04-06. The product was first listed on the ARTG on 2021-04-08.